Related Experiment Video

Updated: Aug 19, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Effect of hepatitis A virus infection on cell metabolism in vitro

V Gauss-Müller, F Deinhardt

    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
    |January 1, 1984
    PubMed

    Abstract:

    Hepatitis A virus (HAV), when inoculated into cultures of the PLC/PRF/5 cell line which produces the surface antigen of hepatitis B virus (HBsAg), showed growth characteristics different from those of other picornaviruses. Antigen of HAV (HAAg) is expressed only about 10 days after infection. No major impact on the overall macromolecular biosynthesis of the host cells is observed. The growth rate of HAV-infected and uninfected cells was comparable, although the plating efficiency of infected cells was lower. Different hormonal factors were tested for their ability to stimulate viral antigen expression. Dexamethasone or prostaglandin E1 added to the culture medium increased HAAg expression; insulin reduced expression. Persistent infection of hepatoma cells by HAV never led to a cytolytic infection. In temperature-shift experiments, an adverse effect on the expression of HAAg and HBsAg was observed. In all experiments, the amounts of HBsAg in HAV-infected cells were reduced. On the whole, no major influence on host-cell metabolism is observed in cells persistently infected with HAV. Cell-mediated immunological response as a mechanism of pathological changes in HAV-infected liver is, therefore, more likely than a cytopathological effect.

    More Related Videos

    Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
    09:02

    Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

    Published on: June 5, 2020

    A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
    08:35

    A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

    Published on: May 18, 2021

    Related Experiment Videos

    Last Updated: Aug 19, 2026

    "Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
    10:25

    "Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

    Published on: February 19, 2019

    Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
    09:02

    Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

    Published on: June 5, 2020

    A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
    08:35

    A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

    Published on: May 18, 2021

    Related Concept Videos

    Hepatitis01:25

    Hepatitis

    Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
    Viral Hepatitis I: Introduction01:28

    Viral Hepatitis I: Introduction

    Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

    Articles linked to this work by shared authors, journal, and citation graph.

    Hepatitis A virus (HAV) proteinase 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein.

    Journal of viral hepatitis·2009

    Perinuclear accumulation of hepatitis A virus proteins, RNA, and particles and ultrastructural alterations in infected cells.

    Archives of virology·2002

    Experimental hepatitis A virus infection in guinea pigs.

    Journal of medical virology·2001

    A new G-tailing method for the determination of the poly(A) tail length applied to hepatitis A virus RNA.

    Nucleic acids research·2001

    Mapping of protein domains of hepatitis A virus 3AB essential for interaction with 3CD and viral RNA.

    Virology·1999

    Improving proteolytic cleavage at the 3A/3B site of the hepatitis A virus polyprotein impairs processing and particle formation, and the impairment can be complemented in trans by 3AB and 3ABC.

    Journal of virology·1999

    Decreased cerebrospinal fluid TNFRSF8 (sCD30) confirmed as a biomarker of Huntington's disease progression.

    Journal of neurology·2026

    Behavioural antimicrobial stewardship interventions in outpatient settings: a systematic review and meta-analysis of physician-targeted approaches.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026

    A brief history of gene therapy for ornithine transcarbamylase deficiency.

    Molecular genetics and metabolism·2026

    Future management of hemophilia a with non-biologic hemostatic agents: a call for precision coagulation.

    Expert opinion on pharmacotherapy·2026

    The efficacy of 1064-nm Nd: YAG picosecond laser for Becker's nevus: a retrospective analysis of 49 cases.

    Lasers in medical science·2026

    Harnessing the Folding of Antitumor Peptides for Controlled Carrier-Free Drug Delivery.

    Small (Weinheim an der Bergstrasse, Germany)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us